Elicera Therapeutics AB (publ) (ELIC.ST)
SEK 3.05
(-1.61%)
SEK 3.05
(-1.61%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -17.08 Million SEK | 11.47% |
| 2022 | -19.42 Million SEK | -47.22% |
| 2021 | -13.1 Million SEK | -365.34% |
| 2020 | -2.81 Million SEK | -1350.07% |
| 2019 | 3190.00 SEK | -5418.47% |
| 2018 | - SEK | 3.83% |
| 2017 | -1304.00 SEK | 16.63% |
| 2016 | -424.00 SEK | -1781.99% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.33 Million SEK | -13.07% |
| 2024 Q2 | -6.82 Million SEK | -4.72% |
| 2023 Q4 | -5.23 Million SEK | -5.17% |
| 2023 Q3 | -4.98 Million SEK | -15.28% |
| 2023 FY | - SEK | -46.73% |
| 2023 Q1 | -2.26 Million SEK | 41.91% |
| 2023 Q2 | -4.32 Million SEK | -90.97% |
| 2022 Q2 | -3.63 Million SEK | 23.2% |
| 2022 Q1 | -4.73 Million SEK | -121.48% |
| 2022 FY | - SEK | -47.22% |
| 2022 Q4 | -3.89 Million SEK | 44.55% |
| 2022 Q3 | -7.02 Million SEK | -93.06% |
| 2021 Q3 | -6.75 Million SEK | -271.78% |
| 2021 Q2 | -1.81 Million SEK | 24.39% |
| 2021 FY | - SEK | -365.34% |
| 2021 Q1 | -2.4 Million SEK | 7.28% |
| 2021 Q4 | -2.13 Million SEK | 68.31% |
| 2020 Q1 | -4900.00 SEK | 0.0% |
| 2020 FY | - SEK | -1350.07% |
| 2020 Q4 | -2.59 Million SEK | -1126.8% |
| 2020 Q3 | -211.13 Thousand SEK | -1897.46% |
| 2020 Q2 | -10.57 Thousand SEK | -115.71% |
| 2019 FY | - SEK | -5418.47% |
| 2018 FY | - SEK | 3.83% |
| 2017 FY | - SEK | 16.63% |
| 2016 FY | - SEK | -1781.99% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | 61.072% |
| Amniotics AB (publ) | -27.14 Million SEK | 37.057% |
| BioArctic AB (publ) | 275.38 Million SEK | 106.204% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 95.355% |
| Camurus AB (publ) | 562.54 Million SEK | 103.037% |
| Cantargia AB (publ) | -284.31 Million SEK | 93.991% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 12.741% |
| CombiGene AB (publ) | -35.33 Million SEK | 51.651% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 87.871% |
| Genovis AB (publ.) | 64.57 Million SEK | 126.458% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 85.132% |
| Mendus AB (publ) | -97.84 Million SEK | 82.539% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 53.856% |
| Intervacc AB (publ) | -68.98 Million SEK | 75.233% |
| Kancera AB (publ) | -61.88 Million SEK | 72.395% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 36.211% |
| LIDDS AB (publ) | -39.67 Million SEK | 56.933% |
| Lipum AB (publ) | -37.11 Million SEK | 53.974% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -41.148% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 154.402% |
| NextCell Pharma AB | -40.98 Million SEK | 58.315% |
| OncoZenge AB (publ) | 7.26 Million SEK | 335.13% |
| Saniona AB (publ) | -69.69 Million SEK | 75.487% |
| Simris Alg AB (publ) | -22.36 Million SEK | 23.604% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 94.618% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 93.942% |
| Xintela AB (publ) | -53.47 Million SEK | 68.049% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 89.939% |
| Ziccum AB (publ) | -20.34 Million SEK | 16.014% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -20.17% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 854325.55% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 92.81% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -721.371% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -27.202% |
| Corline Biomedical AB | -1.69 Million SEK | -910.32% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 90.143% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 68.827% |
| Aptahem AB (publ) | -10 Million SEK | -70.688% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 247.931% |
| Fluicell AB (publ) | -25.91 Million SEK | 34.072% |
| Biovica International AB (publ) | -119.5 Million SEK | 85.704% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 59.538% |
| AcouSort AB (publ) | -16.7 Million SEK | -2.284% |
| Abliva AB (publ) | -93.6 Million SEK | 81.749% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 94.646% |
| 2cureX AB (publ) | -35.13 Million SEK | 51.376% |
| I-Tech AB | 30.34 Million SEK | 156.301% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 97.609% |
| Cyxone AB (publ) | -20.41 Million SEK | 16.31% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 83.325% |
| Biosergen AB | 228 Thousand SEK | 7593.207% |
| Nanologica AB (publ) | -62.11 Million SEK | 72.497% |
| SynAct Pharma AB | -222.7 Million SEK | 92.328% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 61.049% |
| BioInvent International AB (publ) | -312.7 Million SEK | 94.537% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 5621.588% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 40778.376% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 92.624% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -93.867% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 84.262% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -48.963% |